SHL Telemedicine Ltd.

NasdaqCM:SHLT Stock Report

Market Cap: US$45.8m

SHL Telemedicine Valuation

Is SHLT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SHLT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SHLT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SHLT's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SHLT?

Key metric: As SHLT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SHLT. This is calculated by dividing SHLT's market cap by their current revenue.
What is SHLT's PS Ratio?
PS Ratio0.8x
SalesUS$55.94m
Market CapUS$45.76m

Price to Sales Ratio vs Peers

How does SHLT's PS Ratio compare to its peers?

The above table shows the PS ratio for SHLT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.9x
CCEL Cryo-Cell International
2.1x1.0%US$68.0m
CCM Concord Medical Services Holdings
0.3xn/aUS$21.7m
ME 23andMe Holding
0.4xn/aUS$82.0m
AMS American Shared Hospital Services
0.8x18.8%US$19.4m
SHLT SHL Telemedicine
0.8xn/aUS$40.7m

Price-To-Sales vs Peers: SHLT is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does SHLT's PS Ratio compare vs other companies in the US Healthcare Industry?

33 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$76.96b
CVS CVS Health
0.2x4.7%US$66.93b
COR Cencora
0.2x6.4%US$47.09b
CNC Centene
0.2x5.6%US$29.01b
SHLT 0.8xIndustry Avg. 0.9xNo. of Companies33PS012345+
33 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SHLT is good value based on its Price-To-Sales Ratio (0.8x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is SHLT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SHLT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SHLT's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$5.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$76.22

7D

-9.3%

1Y

10.3%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$56.05

7D

0.4%

1Y

-17.9%

Patterson Companies

US$1.7b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$20.90

7D

-0.7%

1Y

-34.7%